Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V118E
- Development stage
- Phase 1
- Lead developer
- Merck
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
V118E is an investigational **pneumococcal vaccine formulation** developed by Merck for prevention of disease caused by *Streptococcus pneumoniae*. It is being evaluated in a randomized, double-blind Phase 1 study in healthy adults for safety, tolerability, and immunogenicity. In the registered study, V118E is administered as a two-dose intramuscular regimen on Day 1 and Day 29, with PREVNAR 20 plus saline used as a comparator regimen. Its precise antigen composition, valency, carrier proteins, and adjuvant system have not been publicly specified.
- Other names
- V118 formulation EV-118 formulation EV 118 formulation E
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)
Beyond the preview
Go deeper on V118E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V118E.